Bilaketaren emaitzak - Heather Oakervee

  • Erakusten 1 - 13 emaitzak -- 13
Findu emaitzak
  1. 1
    Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

    Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up nork Rakesh Popat, Heather Oakervee, Simon Hallam, Nicola Curry, Liz Odeh, Nicola Foot, Dixie‐Lee Esseltine, Mary Drake, Curly Morris, Jamie Cavenagh

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Advanced Imaging Modalities to Monitor for Cardiotoxicity

    Advanced Imaging Modalities to Monitor for Cardiotoxicity nork Andreas Seraphim, Mark Westwood, Anish Bhuva, Tom Crake, James Moon, Leon Menezes, Guy Lloyd, Arjun K. Ghosh, Sarah Slater, Heather Oakervee, Charlotte Manisty

    Argitaratua 2019
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

    PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma nork Heather Oakervee, Rakesh Popat, Nicola Curry, Pat Smith, Curly Morris, Mary Drake, Samir Agrawal, Jim Stec, David P. Schenkein, Dixie‐Lee Esseltine, Jamie Cavenagh

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

    Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial nork Rakesh Popat, Sarah Brown, Louise Flanagan, Andrew Hall, Walter M. Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh

    Argitaratua 2016
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

    A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma nork Jamie Cavenagh, Heather Oakervee, P Baetiong-Caguioa, Faith E. Davies, Mecide Gharibo, Neil Rabin, Michael R. Kurman, Barbara Novak, Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Kwee Yong

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction

    Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction nork David Taussig, Jacques Vargaftig, Farideh Miraki‐Moud, Emmanuel Griessinger, Kirsty Sharrock, Tina Luke, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, Tim Lister, John G. Gribben, Dominique Bonnet

    Argitaratua 2010
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

    Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells nork David Taussig, Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Daniel J. Pearce, Kirsty Allen, Christopher M. Ridler, Debra M. Lillington, Heather Oakervee, Jamie Cavenagh, Samir Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet

    Argitaratua 2008
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Differential and tumor-specific expression of CD160 in B-cell malignancies

    Differential and tumor-specific expression of CD160 in B-cell malignancies nork Timothy Farren, Jérôme Giustiniani, Fengting Liu, Dimitris A. Tsitsikas, Marion G. Macey, James D. Cavenagh, Heather Oakervee, David Taussig, Adrian C. Newland, Maria Calaminici, Armand Bensussan, Michael Jenner, John G. Gribben, Samir Agrawal

    Argitaratua 2011
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation

    Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation nork Farideh Miraki‐Moud, Fernando Anjos‐Afonso, Katharine Hodby, Emmanuel Griessinger, Guglielmo Rosignoli, Debra M. Lillington, Li Jia, Jeff Davies, Jamie Cavenagh, Matthew L. Smith, Heather Oakervee, Samir Agrawal, John G. Gribben, Dominique Bonnet, David Taussig

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients

    Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients nork James Aries, Jeffrey K. Davies, Rebecca L. Auer, Simon Hallam, Silvia Montoto, Matthew D. Smith, Belen Sevillano, Vanessa Foggo, Bela Wrench, Krzysztof Zegocki, Samir Agrawal, Rifca Le Dieu, Edward Truelove, Thomas Erblich, Shamzah Araf, Jessica Okosun, Heather Oakervee, Jamie Cavenagh, John G. Gribben, John C. Riches

    Argitaratua 2020
    Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  11. 11
    Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

    Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma nork Ivan Špıčka, Enrique M. Ocio, Heather Oakervee, Richard Greil, Raymond H. Banh, Shang‐Yi Huang, James M. D’Rozario, Meletios Α. Dimopoulos, Sara Martínez, Sonia Extremera, Carmen Kahatt, Vicente Alfaro, Angelo Michele Carella, Nathalie Meuleman, Roman Hájek, Argiris Symeonidis, Chang‐Ki Min, Paul Cannell, Heinz Ludwig, Pieter Sonneveld, María‐Victoria Mateos

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma nork Sagar Lonial, Meletios Α. Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Philippe Moreau, María‐Victoria Mateos, Hila Magen, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesús F. San Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul G. Richardson

    Argitaratua 2015
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study nork Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C. Anderson, Ying‐Ming Jou, Alex Ganetsky, Anil Singhal, Paul G. Richardson

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: